Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

I-MOVE-COVID-19 primary care study team, I-MOVE-COVID-19 primary care study team (in addition to authors above)

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.

Original languageEnglish
Article number2100670
Number of pages7
JournalEurosurveillance
Volume26
Issue number29
DOIs
Publication statusPublished - 22 Jul 2021

Keywords

  • COVID-19
  • Europe
  • multicentre study
  • SARS-CoV-2
  • test-negative design
  • vaccine effectiveness

Fingerprint

Dive into the research topics of 'Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021'. Together they form a unique fingerprint.

Cite this